Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Zachs Small-Cap Research RAD Initiating Coverage – Adding a Radio- isotope to Precision Oncology

Tuesday, May 13, 2025 1 min read
Key Takeaway: Radiopharm Theranostics is making strides in precision oncology with its BetaBart (RV-01) program. The company has received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3. Additionally, they have dosed the first patient in a Phase 1/2a clinical study, showcasing progress in their clinical pipeline.
Price reaction · baseline $3.96 (2025-05-13T18:38:00.000Z) · hit during market hours · clean, no other RADX news in the window
day 0 close · peak
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics is advancing its clinical programs.
  • The company has received IND approval from the US FDA.
  • Positive updates across multiple clinical programs are noted.

Full Press Release Details

• Analyst Reports
• PDF
• May 13, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• June 21, 2022
• Announcements
• October 18, 2023
• Announcements
• August 23, 2024
• Announcements
• November 29, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is BetaBart (RV-01)?

BetaBart (RV-01) is a therapeutic targeting B7H3 developed by Radiopharm Theranostics.

What recent approval did Radiopharm receive?

Radiopharm Theranostics received IND approval from the US FDA for BetaBart.

What phase is the BetaBart clinical study in?

The BetaBart clinical study is currently in Phase 1/2a.

Who was appointed to the advisory board?

Dr. Oliver Sartor was appointed to the Radiopharm Scientific Advisory Board.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart precision oncology clinical study FDA approval
Last updated: May 13, 2025